Signed by Governor Kevin Stitt

Vote Smart's Synopsis:

Vote to concur with Senate amendments and pass a bill that authorizes clinical trials for the drug Ibogaine in Oklahoma.

Highlights:

• Requires the State Department of Health to develop multistate drug development clinical trials in contract with drug developers to obtain FDA approval for the use of ibogaine (Sec. 3). 

• Requires the following to be provided by drug developers if they are to enter contract with the State Department of Health (Sec. 3):

• A detailed description of their strategy for obtaining FDA approval for ibogaine;

• Protocols for clinical trial participant recruitment, patient screening criteria administration, aftercare, and post-acute treatment support;

• Certification of an existing ibogaine drug development agreement with one or more other states or state-sponsored consortia; and

• Financial disclosures sufficient to verify the drug developer is prepared to meet its full obligations under this section.

• Requires that all contracts with drug developers include (Sec. 3):

• Additional funds to match state investments into ibogaine that are meant to be used for in-state clinical trials;

• Progress and financial reports; and

• A detailed plan to ensure accessible ibogaine treatment that includes priority access to Oklahoma residents, third-party payor approval, developing means of access for uninsured and low-income individuals, and training and credentialing for medical providers.

• Specifies that the State of Oklahoma will, in their multistate drug development clinical trials, accrue certain intellectual property rights (Sec. 3).

• Establishes an “Ibogaine Development Revolving Fund” to keep funds generated by intellectual property rights, legislative appropriations, private gifts and donations, and public and private grants Sec. 4).

• Specifies that this Act is effective November 1, 2026 (Sec. 7).

Full Bill Text

Vote Smart's Synopsis:

Vote to amend and pass a bill that authorizes clinical trials for the drug Ibogaine in Oklahoma.

Highlights:

• Requires the State Department of Health to develop multistate drug development clinical trials in contract with drug developers to obtain FDA approval for the use of ibogaine (Sec. 3). 

• Requires the following to be provided by drug developers if they are to enter contract with the State Department of Health (Sec. 3):

• A detailed description of their strategy for obtaining FDA approval for ibogaine;

• Protocols for clinical trial participant recruitment, patient screening criteria administration, aftercare, and post-acute treatment support;

• Certification of an existing ibogaine drug development agreement with one or more other states or state-sponsored consortia; and

• Financial disclosures sufficient to verify the drug developer is prepared to meet its full obligations under this section.

• Requires that all contracts with drug developers include (Sec. 3):

• Additional funds to match state investments into ibogaine that are meant to be used for in-state clinical trials;

• Progress and financial reports; and

• A detailed plan to ensure accessible ibogaine treatment that includes priority access to Oklahoma residents, third-party payor approval, developing means of access for uninsured and low-income individuals, and training and credentialing for medical providers.

• Specifies that the State of Oklahoma will, in their multistate drug development clinical trials, accrue certain intellectual property rights (Sec. 3).

• Establishes an “Ibogaine Development Revolving Fund” to keep funds generated by intellectual property rights, legislative appropriations, private gifts and donations, and public and private grants Sec. 4).

• Specifies that this Act is effective November 1, 2026 (Sec. 7).

Full Bill Text